Vivosim Labs, INC. quarterly report, Q3 FY2023

Filing identity and reporting period

The supplied filing is Organovo Holdings, Inc.’s Form 10-Q for the quarter ended December 31, 2023, filed February 8, 2024. This does not match the request metadata identifying Vivosim Labs, Inc. and 2022 Q3; the summary below reflects the filing text provided.

Business context

Organovo is a clinical-stage biotechnology company focused on FXR314, an FXR agonist being developed for inflammatory bowel disease, and on 3D human tissue disease models. Management planned to begin a Phase 2a ulcerative colitis trial in calendar 2024. The statements are unaudited; the nine-month period is the first nine months of fiscal 2024.

Financial results and liquidity

• Nine-month R&D expense was $4.435 million; SG&A was $7.635 million. Royalty revenue was the only reported revenue, so conventional gross margin is not meaningful.
• At December 31, 2023, cash and cash equivalents were $5.295 million, restricted cash was $143,000, current assets were $6.241 million, current liabilities were $1.700 million, and working capital was $4.541 million. Total assets were $8.881 million.
• Total liabilities were $2.699 million, including $1.501 million of operating lease liabilities. The filing reports no outstanding borrowings or other financial debt.
• Cash, cash equivalents and restricted cash fell by $10.006 million over the nine months. Financing provided $1.173 million, primarily from ATM stock sales.
• Management reported substantial doubt about the company’s ability to continue as a going concern for at least one year after issuance, and said substantial additional funding would be needed.

Changes versus comparable periods

• Quarterly revenue declined 96% from $131,000 to $5,000; nine-month revenue declined 62% from $208,000 to $80,000. Management attributed the decrease to lower sales by the royalty licensee and expected that trend to continue.
• Quarterly net loss widened from $3.264 million to $3.604 million; nine-month net loss widened from $9.800 million to $11.626 million.
• Nine-month R&D expense rose 29% to $4.435 million, reflecting increased clinical-development activity and related personnel, lab, consulting and facility costs. Nine-month SG&A rose 14% to $7.635 million, mainly due to higher legal and investor-relations expenses.
• Cash used in operations increased to $11.982 million from $7.675 million. Management cited increased R&D activity and $2.0 million paid for acquired in-process R&D related to Metacrine’s FXR compound, research data and intellectual property.
• Cash and cash equivalents declined from $15.301 million at March 31, 2023. Working capital decreased from $13.377 million to $4.541 million.

Outlook, risks and unusual items

• Management forecast fiscal-year 2024 operating expenses of $13 million to $15 million and anticipated increased costs as it advances FXR314. It did not provide revenue or earnings guidance.
• In August 2023, the company reduced its workforce by approximately six employees, or 24% of staff at the time. It recorded $380,000 of restructuring charges for the nine months, expected about $400,000 of cash severance costs through March 31, 2024, and projected annual savings of $1.5 million.
• During the quarter, the company issued 934,621 shares through its ATM program. After quarter-end through the filing date, it issued another 201,319 shares for approximately $200,000 net proceeds. It also filed a new $150 million shelf registration statement and a limited ATM prospectus; the new shelf had not yet been declared effective.
• Key risks include the going-concern funding gap, potential dilution or unfavorable financing terms, uncertain clinical-trial outcomes and timing, unproven disease-model technology, reliance on third parties and human-cell supplies, and dependence on a single royalty licensee.
• The filing reported no accrued legal contingency and no determination that an unfavorable legal outcome was probable or reasonably possible, while cautioning that litigation outcomes remain uncertain. Management said disclosure controls were effective and reported no material change in internal control over financial reporting during the quarter.

Most important facts for investors to verify

1. Confirm the issuer and period: the provided text is Organovo Holdings’ December 31, 2023 quarter, not Vivosim Labs’ 2022 Q3 filing.
2. Review the going-concern disclosure, cash balance, operating cash burn and the company’s plans and ability to secure additional capital.
3. Track whether the planned 2024 Phase 2a ulcerative colitis trial starts, and monitor its costs, enrollment and reported results.
4. Assess continuing ATM or other securities issuance, available financing capacity and resulting dilution.
5. Check whether royalty revenue continues to decline and whether restructuring savings and expense guidance are achieved.